tbuckley/cabot-search huggingface dataset:
Neoadjuvant chemoradiotherapy for potentially resectable esophageal squamous cell carcinoma and the significance of Rad51 expression as a factor predictive of the treatment response.
Authors: Hiroshi Saeki, Tomonori Nakanoko, Hajime Ohtsu, Hiroyuki Kawano, Koji Ando, Eiji Oki, Takefumi Ohga, Masaru Morita, Yoshihiro Kakeji, Yasushi Toh, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2012)

e14601 Background: The clinical significance of neoadjuvant chemoradiotherapy (NACRT) for potentially resectable esophageal squamous cell carcinoma (ESCC) and its effect on the development of postoperative complications are unclear. On the other hand, the Rad51 expression is related to the sensitivity to chemotherapy or radiotherapy; however, the significance of the Rad51 expression in ESCC has not yet been clarified. Methods: 1) One hundred sixty-eight patients with clinical Stage II-III (cStageII-III) ESCC were classified into two groups consisting of 76 who received NACRT followed by esophagectomy and 92 patients who received surgery alone. The prognosis and incidence of postoperative complications were retrospectively compared between the two groups. The pathological response to NACRT as well as the patient prognosis were also analyzed for the NACRT group patients. 2) The expression of Rad51 was investigated in pretreatment biopsy specimens in 41 ESCC cases who underwent surgery after NACRT, and the findings were compared with the pathological response to NACRT. Results: 1) The 5-year survival rate was 47.7% in the surgery alone group and 56.5% in the NACRT group, and the difference was not a statistically significant (p=0.4831). However, the 5-year survival rates of patients in whom NACRT was Grade 3 (markedly effective), was obviously better than that of the other patients (Grade0/1 – ineffective/slightly effective: 36.9%, Grade 2 - moderately effective: 53.8%, Grade 3 - markedly effective: 100%). The incidence of postoperative complications was 31.5% in the surgery alone group and 40.8% in the NACRT group, and the difference was not a statistically significant (p=0.2121). 2) Grade 3 was more frequently observed in Rad51-negative cases (n=13) than Rad51-positive cases (n=28; 71.4% vs. 28.6%, p=0.0239). Conclusions: The pathological complete response of NACRT is critical for improving the survival of patients with cStageII-III ESCC. The Rad51 expression in pretreatment biopsy specimens was therefore suggested to be a useful predictive factor for the response to NACRT.
GENDER DIFFERENCES IN SHORT- AND LONG-TERM MORTALITY IN THE VIENNA STEMI REGISTRY
Authors: Edita Piacková, Bernhard Jäger, Serdar Farhan, Günter Christ, Wolfgang Schreiber, Franz Weidinger, Thomas Stefenelli, Georg Delle-Karth, Alfred Kaff, Gerald Maurer, Kurt Huber
Journal: Journal of the American College of Cardiology (2017)
Clinical implication of distinction from clinical features and treatment outcome of malignant lymphoma in Korean childhood and young adult
Authors: I. Hwang, K. Yoo, S. Lee, S. Park, B. Park, Y. Ko, K. Kim, K. Park, H. Koo, W. Kim
Journal: Journal of Clinical Oncology (2007)

18534 Background: The Clinicopathologic features of malignant lymphomas vary to geography and differ to age. The goal of this study was to find the implication of distinction from biology, clinical features and treatment outcome of malignant lymphoma in childhood and young adult. Methods: We analysed the clinical features including age, gender, histologic type, and treatment outcome of 294 children and young adults during 13-year period (from May 1993 to November 2005) in Samsung medical center and compared our study to all age group and western childhood and adolescence group on clinical features or treatment outcome in malignant lymphoma. Results: Median age at diagnosis was 20.7 years (range: 0.1–30.1 years). Male to female ratio was 1.37:1, Of 294 cases, there were 248 cases of non-hodgkin’s lymphoma (NHL) (84.3%) and 44 cases of hodgkin’s disease (HD) (15%). This rate was significantly different to rate of all age group (HD= 5.3%) (p=0.001). Of 248 cases of non-hodgkin’s lymphoma, 134 cases (54.0%) were B-lineage and 113 cases (45.6%) were T- or NK-cell lineage. Our study group had higher rates of T- or NK-cell NHL compared to all age group (p=0.001) and western group (p=0.001). Among 248 cases of NHL, the most common histologic type was diffuse large cell lymphoma (DLBL) in our study group. Burkitt’s lymphoma (BL) was the most common histologic types in Western study group. 5-year survival rate (5YSR) was 80.4% and was superior for BL and was inferior for NK/T cell lymphoma. However male T-LBL patients had better outcome in western study group. NHL and T-cell NHL had significantly worse outcomes than HD and B-cell NHL (p=0.049, 0.001, respectively). Comparing age-groups 0–10, 10–20 and 20–30, 5YSR was inferior for the oldest patients only in NHL-, T-cell NHL- and T-cell LBL-groups. Conclusions: Our study suggested environmental and genetic factor was associated with the development of malignant lymphoma. No significant financial relationships to disclose.
SERUM SODIUM IS ASSOCIATED WITH MORTALITY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE U.S. VETERAN POPULATION
Authors: Tasnim F. Imran, Katherine E. Kurgansky, Yash Patel, Ariela Orkaby, Robert McLean, Kelly Cho, David R. Gagnon, Yuk-Lam Ho, J. Michael Gaziano, Luc Djousse, Jacob Joseph
Journal: Journal of the American College of Cardiology (2017)
CONTEMPORARY TRENDS AND OUTCOMES OF ISOLATED AORTIC VALVE REPLACEMENT IN FEMALES IN THE UNITED STATES: UNDERSTANDING THE GENDER GAP
Authors: Fahad Alqahtani, Vinay Badhwar, Ahmed Almustafa, Sami Aljohani, Zakeih Chaker, Almoutassim Trabulsi, Ali Hama Amin, Mohammad Akram Kawsara, Mohamad Alkhouli
Journal: Journal of the American College of Cardiology (2017)
ASSOCIATION BETWEEN SYNTAX SCORE, AND PRE- AND POST-STENTING OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN STABLE ANGINA PATIENTS
Authors: Krzysztof Bryniarski, Yamamoto Erika, Jiannan Dai, Thomas Zanchin, Tomoyo Sugiama, Lei Xing, Hang Lee, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2017)
Correlation of TOP2A expression in HER2-positive breast cancer with pathologic response and clinical outcomes in patients undergoing neoadjuvant treatment based on anthracycline.
Authors: Elizabeth S. Santos, Felipe D'Almeida Costa, Stephania Bezerra, Rafael Costa Lessa, Vladmir Claudio Cordeiro De Lima, Debora De Melo Gagliato, Geraldine Eltz Lima, Marcello Ferretti Fanelli, Rafael Malagoli Rocha, Alexandre Andre Balieiro da Costa, Augusto Akikubo Rodrigues Pereira, Fernando Vidigal Padua, Carlos Eduardo Pires Sousa, Paulo Henrique Aires Freitas, Flavio Augusto Ismael Pinto, Newton Augusto Ferreira Rodrigues, Carlos Frederico Lopes Benevides
Journal: Journal of Clinical Oncology (2012)

643 Background: Factors predictive of response to anthracyclines can help selecting patients who really benefit from its use. TOP2A (a target of anthracyclines) and HER2 genes are both amplified in 40% of breast cancers. Data from literature are conflicting regarding the potential of TOP2A as a predictor of response to anthracyclines. Methods: We retrospectively analyzed data on the outcome of patients undergoing neoadjuvant anthracycline-based chemotherapy and evaluated nuclear TOP2A protein expression in breast cancer biopsies by immunohistochemistry (IHC) and reviewed the pathological responses after completion of neoadjuvant treatment. Results: From 2002 to 2011, data from 82 patients was reviewed. Forty nine patients had the paraffin blocks corresponding to the pre-treatment biopsy. All biopsies had some degree of TOP2A IHC expression. Patients were considered positive for TOP2A if the level of expression in IHC was higher than 10%. This was found in 77.6% of cases. Forty percent of the patients achieved pathologic complete response in pos-treatment surgical specimens. Correlation was observed between TOP2A IHC expression and tumor pathological response (p0.02). It was observed a difference in pathological complete response in favour of the group positive for TOP2A (47.4% vs. 22.7%), although not significant (p=0.09). No difference in PFS and OS was observed between patients with complete response after median follow-up of 34 months. Conclusions: The expression of TOP2A seems to be a promising marker to predict pathological response to antracycline-based neoadjuvant chemotherapy in HER2 breast cancer; however these findings would be better evaluated in prospective trials.
The Novel Missense Mutation of GATA1 Caused Red Cell Adenosine Deaminase Overproduction Associated with Congenital Hemolytic Anemia
Authors: Hiromi Ogura, Toshiyuki Yamamoto, Taiju Utsugisawa, Takako Aoki, Takuya Iwasaki, Yumiko Ondo, Takahiro Kawakami, Shinichiro Nakagawa, Shuichi Ozono, Hiroko Inada, Hitoshi Kanno
Journal: Blood (2016)
Misdiagnosis certainly occurs
Authors: N. L Childs, W. N Mercer
Journal: BMJ (1996)

The second message of the study is that the term persistent vegetative state is widely misused, even in recent papers.3No clinician should accept a diagnosis of such a state within 12 months of the onset of coma.I strongly recommend use of the term "continuing vegeta- tive state," or even the simpler term "coma," for all patients who are comatose over the first 12 months after the onset of coma.In this way clini- cians and relatives will avoid drawing premature or incorrect conclusions from loosely applied diagnostic labels.
EDUCATIONAL STRATEGY FOR MANAGEMENT OF HEART FAILURE MARKEDLY REDUCES 90-DAY EMERGENCY DEPARTMENT AND HOSPITAL READMISSIONS IN UN- AND UNDERINSURED PATIENTS
Authors: Vishwaratn Asthana, Miel Sundararajan, Vivek Karun, Ruth Ackah, Arunima Misra, Allison Pritchett, Angela Siler-Fisher, W. Frank Peacock
Journal: Journal of the American College of Cardiology (2017)
The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study—N05C3<sup>1</sup>
Authors: L. A. Kottschade, J. A. Sloan, M. A. Mazurczak, D. B. Johnson, B. Murphy, K. M. Rowland, D. A. Smith, A. Berg, P. J. Stella, C. L. Loprinzi
Journal: Journal of Clinical Oncology (2009)

9532 Background: Chemotherapy induced peripheral neuropathy (CIPN) continues to be a substantial problem for many cancer patients (pts). Pursuant to promising appearing pilot data, the current study evaluated the use of vitamin E for the prevention of CIPN. Methods: A phase III, randomized, double-blind, placebo controlled study was conducted in pts undergoing therapy with neurotoxic chemotherapy, utilizing twice daily dosing of vitamin E (400mg)/placebo. The primary endpoint was the incidence of grade 2+ sensory neuropathy (SN) toxicity (CTCAE v 3.0) in each treatment arm, analyzed by Chi-square testing. Major eligibility criteria included: planned curative intent adjuvant chemotherapy with neurotoxic chemotherapy, ≥ 18 years of age, ECOG PS of ≤2, no existing peripheral neuropathy or coronary artery disease, no prior treatment with neurotoxic chemotherapy, and no concurrent treatment with neuropathic or opioid pain medication. Planned sample size was 100 patients per arm, to provide 80% power to detect a difference in incidence of grade 2+ SN toxicity from 25% in the placebo group to 10% in the vitamin E group. Results: Two-hundred seven pts were enrolled between 12/01/2006 and 12/14/2007. Cytotoxic agents included taxanes (109), cisplatin (8), carboplatin (2), oxaliplatin (50) or combination (20). Eleven pts canceled prior to starting treatment and there were 7 ineligible pts on study. Thus there were 189 evaluable pts included in the current analysis. In this analysis, there was no difference in the incidence of grade 2+ SN between the 2 arms (vitamin E- 34% [95% CI- 25.0–44.8%] placebo- 29% [20.1–39.4%]; P=0.43). There, likewise, were no significant differences between treatment arms for time to onset of neuropathy (P= 0.72), for chemotherapy dose reductions due to neuropathy (P= 0.21) or patient questionnaire reported neuropathy symptoms. The treatment was well tolerated overall. Conclusions: Vitamin E did not appear to reduce the incidence of sensory neuropathy in the studied group of patients receiving neurotoxic chemotherapy but it appeared to be well tolerated. No significant financial relationships to disclose.
Hidden DNA Copy Number Alterations and Mutations in IKZF1, TP53, CRLF2 and JAK2 Genes Are Associated with a Poor Prognosis in B-Progenitor Acute Lymphoblastic Leukemia
Authors: Jesús María Hernández-Rivas, Maribel Forero, Cristina Robledo, Rocio Benito, María Hernández, María Abáigar, Ana Rodríguez, Luis A. Corchete, Ana Martín, Susana Riesco-Riesco, A García-de-Coca, José L. Fuster, Natalia De-las-Heras, Juan N. Rodríguez, I De-la-Fuente, Josep-Maria Ribera, Jordi Ribera, Jorge Labrador, Jose M. Alonso, Juan L. García, Consuelo Del CaÃ±izo
Journal: Blood (2014)
Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin’s Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors.
Authors: Paolo Anderlini, Rima M. Saliba, Sandra Acholonu, Sergio A. Giralt, Issa F. Khouri, Borje Andersson, Marcos De Lima, Chitra Hosing, Daniel Couriel, Richard E. Champlin
Journal: Blood (2006)
CONTEMPORARY OUTCOMES OF ANTERIOR SEGMENT ST-ELEVATION MYOCARDIAL INFARCTION: A LARGE 10-YEAR TERTIARY CARE EXPERIENCE
Authors: Wamiq Y. Banday, M. Fuad Jan, Tadele Mengesha, Robyn L. Shearer, Tanvir Bajwa, Suhail Allaqaband
Journal: Journal of the American College of Cardiology (2017)
CARDIAC AMYLOIDOSIS MASQUERADING AS SEVERE LOW-FLOW, LOW-GRADIENT, LOW-EJECTION FRACTION AORTIC STENOSIS: “ALL THAT GLITTERS IS NOT GOLD”
Authors: Matthew S. Tong, Jose Ricardo Po, Ramzi Khalil, Benjamin Susco, Moneal Shah, Robert Biederman
Journal: Journal of the American College of Cardiology (2017)
THE PROGNOSTIC IMPLICATIONS OF CURRENT PERIPROCEDURAL MYOCARDIAL INFARCTION DEFINITIONS IN PATIENTS UNDERWENT PERCUTANEOUS CONRONARY INTERVENTION WITH UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE
Authors: Jung Ae Hong, Ungjeong Do, Osung Kwon, Kyusup Lee, Do-Yoon Kang, Yu Na Kim, Jae Seok Bae, Min Soo Cho, Cheol Hyun Lee, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2017)
LEFT ATRIAL APPENDAGE OCCLUSION FACILITATED BY THREE DIMENSIONAL ROTATIONAL ANGIOGRAPHY ALONE IS SAFE AND ANATOMICALLY SUPERIOR TO TRASOESOPHAGEAL ECHOCARDIOGRAPHY
Authors: Sofia Chatzikyriakou, Etel Silva Garcia, Martin Penicka, Guy Van Camp, Peter Geelen, Tom De Potter
Journal: Journal of the American College of Cardiology (2017)
Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer?
Authors: William Raskin, Ingrid Harle, Wilma M Hopman, Christopher M. Booth
Journal: Journal of Clinical Oncology (2015)

e20509 Background: Despite being a marker of quality care, documentation of advance directives among patients with terminal cancer is known to be poor. Here we describe the documentation of prognosis, treatment benefit, and goals of care (GOC) discussions in patients with advanced cancer seen in the out-patient setting at a comprehensive cancer centre. Methods: All patients who initiated palliative chemotherapy for metastatic pancreas or lung cancers during 2010-2013 at the Cancer Centre of Southeastern Ontario were identified from electronic pharmacy records. Patients treated with first-line palliative chemotherapy who had at least 4 clinic visits with medical oncology (MO) were eligible. Clinical notes from MO were reviewed to identify documentation of discussions regarding prognosis, treatment benefit, estimates of survival, and GOC. Clinical notes from palliative care (PC) were also reviewed. Differences between groups were tested using the chi-square test. Results: 222 patients were included; 80% (177/222) with lung cancer and 20% (45/222) with pancreas cancer. The mean number of MO clinic visits was 4.6. MO notes documented discussion of prognosis in 64% (142/222), palliative intent of therapy in 82% (182/222), magnitude of treatment benefit in 29% (64/222), and GOC in 4% (9/222) of patients. An estimate of survival was documented in 36% (79/222) of cases. Across MO providers there was substantial variation in frequency of discussing prognosis (range 33-90%, p < 0.001), treatment intent (range 55-100%, p < 0.001), and GOC (range 0-17%, p = 0.034). Only 41% (93/222) of patients were seen by PC; substantial MO provider variation was observed (range 27-58%, p = 0.020). Referral rates to PC did not increase over time (41 to 44%, p = 0.250). Among those patients seen by PC, GOC were documented by PC in 32% (29/93) of cases; substantial PC provider variation was observed (range 0-57%, p = 0.015). Conclusions: In this cohort of patients with an estimated life expectancy of one year or less, MO documentation of prognosis, treatment benefit, and GOC was poor. Less than half of patients were seen by PC. Initiatives to improve documentation of GOC and referral to PC are needed.
Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial
Authors: Paul B. Koller, Koji Sasaki, Farhad Ravandi, Guillermo Garcia-Manero, Susan O'Brien, Jorge E. Cortes, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Jad Chahoud, Allison Pike, Mark Brandt, Sherry Pierce, Hagop M. Kantarjian, Elias Jabbour
Journal: Blood (2015)
PROOF IS IN THE PACLITAXEL: CATHETER DIRECTED INTRACORONARY PACLITAXEL AS SALVAGE THERAPY FOR REFRACTORY CARDIAC ALLOGRAFT VASCULOPATHY
Authors: Rajan Shah, Youssef Nasr, Timothy Raymond, Akshay Khandelwal, Cristina Tita
Journal: Journal of the American College of Cardiology (2017)
Direct Binding of Grb2 Is Required for Efficient Induction of Myeloproliferative Disease in Mice by ETV6/FLT3.
Authors: Kazuhisa Chonabayashi, Masakatsu Hishizawa, Shin Kawamata, Masashi Matsui, Tatsuharu Ohno, Takayuki Ishikawa, Takashi Uchiyama
Journal: Blood (2009)
TEMPORAL SEQUENCE OF ATHLETE'S HEART REGRESSION DURING PRESCRIBED EXERCISE DETRAINING: DIAGNOSTIC IMPLICATIONS
Authors: Charles Pedlar, Marcel Brown, James Otto, Aimee Drane, Jennifer Michaud Finch, Miranda Contursi, Robert Shave, Meagan Wasfy, Adolph Hutter, Aaron Baggish
Journal: Journal of the American College of Cardiology (2017)
Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod, following radio-chemotherapy for newly diagnosed glioblastoma
Authors: L. M. Liau, R. M. Prins, S. K. Odesa, M. Y. Yang, M. S. Lin, H. Khan-Farooqi, H. Soto, A. Lai, M. Bosch, A. Boynton, T. F. Cloughesy
Journal: Journal of Clinical Oncology (2007)

2021 Background: Standard therapy for glioblastoma, which includes surgery followed by radiation and concurrent chemotherapy, creates a low tumor burden environment that could be ideal for immunotherapeutic approaches. We conducted a Phase I study to assess the safety and immunologic responses of tumor lysate-pulsed dendritic cell (DC) therapy plus topical imiquimod, in combination with standard radio-chemotherapy. Methods: Thirteen patients with newly diagnosed glioblastoma were immunized using autologous tumor lysate-pulsed DC. Each patient initially received 3 immunizations at 2-week intervals, following completion of a 6-week course of radio- chemotherapy. Four patients received 1 million DC, 4 received 5 million, and 5 received 10 million DC per immunization. Patients without tumor progression subsequently received booster vaccinations combined with topical administration of the TLR-7 agonist imiquimod. Immunologic responses to tumor antigens were monitored by HLA-restricted tetramer staining, CTL assays, and quantitation of T-regulatory cells. Clinical tumor growth was monitored by brain MRI scans every 2 months, and the primary clinical endpoint was 2-year survival. Results: All immunizations were well tolerated, with only mild side effects attributable to the DC vaccination and imiquimod adjuvant. Increased levels of CD8+ T cells reactive against tumor antigens, (e.g., gp100, TRP-2, her-2, survivin, and CMV antigens), were detected in 5 patients. Median PFS and OS have not been reached in this trial. To date, 6 of the 13 patients have progressed, and 4 of those have died. The median PFS to date is 18.1 mos. and median OS is 33.8 mos. This compares favorably with controls from the published literature, with a median PFS of 6.9 mos and OS of 14.6 mos. Conclusions: This study demonstrates the safety and clinical/immunologic effects of an autologous tumor lysate-pulsed DC vaccine for patients with newly diagnosed glioblastoma. The adjunctive use of the TLR-7 agonist imiquimod with DC vaccination appears to be non-toxic, and deserves further study. We demonstrate that this active immunotherapy strategy can generate antigen-specific immunologic responses in brain tumor patients following standard radio-chemotherapy. No significant financial relationships to disclose.
IMPLICATIONS OF STATIN THERAPY AMONG SMOKERS WITH SEVERE CORONARY ARTERY CALCIFICATION: AN ANALYSIS OF THE CONFIRM REGISTRY
Authors: Khalil Anchouche, Subhi At'Aref, Ashley Beecy, Heidi Gransar, Briain O. Hartaigh, Ji Hyun Lee, Mahn Won Park, Hadi Mirhedayati Roudsari, Donghee Han, Asim Rizvi, Joshua Schulman-Marcus, Fay Lin, James Min, Jessica Pena
Journal: Journal of the American College of Cardiology (2017)
TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH BICUSPID AORTIC VALVE STENOSIS UTILIZING THE NEXT GENERATION FULLY RETRIEVABLE AND REPOSITIONABLE VALVE SYSTEM: EARLY RESULTS FROM THE MULTICENTER POL-TAVI REGISTRY
Authors: Lukasz Koltowski, Janusz Kochman, Radoslaw Parma, Anorzej Ochala, Zenon Huczek, Adam Witkowski, Piotr Scislo, Marek Grygier, Maciej Lesiak, Eberhard Grube, Marian Zembala
Journal: Journal of the American College of Cardiology (2017)
Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)
Authors: Martin Schrappe, Martin Zimmermann, Anja Möricke, Georg Mann, Maria Grazia Valsecchi, Claus R. Bartram, Andrea Biondi, Renate Panzer-Grümayer, Rita Beier, Gunnar Cario, Franco Locatelli, Giuseppe Basso, Felix Niggli, Maurizio Aricò, Valentino Conter
Journal: Blood (2016)
Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control
Authors: Saba Ghassemi, Patel Prachi, John Scholler, Selene Nunez-Cruz, David M. Barrett, Felipe Bedoya, Joseph A. Fraietta, Simon Francis Lacey, Bruce L Levine, Stephen A. Grupp, Carl H June, Michael C. Milone, J. Joseph Melenhorst
Journal: Blood (2016)
A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents
Authors: Nicholas J. Short, Guillermo Garcia-Manero, Kiran Naqvi, Steven M. Kornblau, Abhishek Maiti, Marina Konopleva, Courtney D DiNardo, Koichi Takahashi, Yesid Alvarado, Maro Ohanian, Zeev Estrov, Prithviraj Bose, Michael Andreeff, Rabiul Islam, Xiao Dong, Jorge E. Cortes, Hagop M. Kantarjian, Elias J. Jabbour
Journal: Blood (2016)
IMPACT OF MYOCARDIAL INJURY INDICATED BY INCREASED CREATININE KINASE-MYOCARDIAL BAND LEVELS ON THE OUTCOME AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS FROM A PROSPECTIVE SINGLE CENTER REGISTRY
Authors: Stephan Haussig, Felix Woitek, Norman Mangner, Sergey Leontyev, David Holzhey, Friedrich Mohr, Gerhard Schuler, Axel Linke
Journal: Journal of the American College of Cardiology (2017)
SECULAR TRENDS IN REPORTED SUCCESS RATES OF CATHETER ABLATION FOR NON-PAROXYSMAL ATRIAL FIBRILLATION: FINDINGS FROM THE SMASH-AF META-ANALYSIS STUDY COHORT
Authors: George Leef, Andrew Cluckey, Fahd Yunus, Mariam Askari, Ewoud Schuit, Paul Heidenreich, Mintu Turakhia, Alexander Perino
Journal: Journal of the American College of Cardiology (2017)